Member Info for HotblackDesiato

If Mei had licensed 737 they'd have had to announce it here within a day of signing the agreement - https://www.sec.gov/edgar/search/#/dateRange=1y&ciks=0001262104&entityName=MEI%2520Pharma%252C%2520Inc.%2520(MEIP)%2520(CIK%25200001262104)

Sorry, forgot to include this - https://otp.tools.investis.com/clients/uk/sareum_holdings_plc/rns/regulatory-story.aspx?cid=2841&newsid=1732138

Hi Andy - if the BoD sold any shares they'd have to RNS it - they RNS'd their options back in Nov - https://otp.tools.investis.com/clients/uk/sareum_holdings_plc/rns/regulatory-story.aspx?cid=2841&newsid=1730988

Hi Bobbler - I'm guessing OPUS couldn't finance us as it'd be a conflict of interest with SP involved in both companies.

Their plan might be to get as many 'bonus' shares as possible and just sit on them until we get a license deal then benefit massively.

No problem, I've been called worse ;-)

SOG?!?

Anyway, yes it also crossed my mind that it could be deliberately sidelined but surely a company could make more money in the long run by utilising 737.

For anyone still digging for info on who might have licensed 737, I think it's safe to say they are very private and not listed on the NASDAQ etc. If a company makes any deal that would affect their sp they have to notify the SEC and lodge details within 1 day here https://www.sec.gov/edgar/search/#

I searched for various terms that you might expect to find in the license agreement; SRA737, CRT Pioneer Fund or even "An additional fee made up of up to US$1.0 million cash and 500,000 shares" but no luck.

The closest I came was for an unrelated CRT PF deal - https://www.sec.gov/edgar/search/#/q=%2522CRT%2520Pioneer%2520Fund%2522&dateRange=custom&startdt=2023-01-01&enddt=2024-02-18

SRA737 gets mentioned by Acrivon Therapeutics but only as an example of competing CHK1 inhibitors - https://www.sec.gov/edgar/search/#/q=%2522SRA737%2522&dateRange=custom&startdt=2023-01-01&enddt=2024-02-18

We know there are plenty of reasearch papers all citing encouraging results using 737 so I find it strange that whoever now holds it is playing their cards very close to their chest. If it's been renamed we'll just have to look out for new CHK1 clinical trials.

Sierra are still operating as a subsidiary of GSK but are otherwise totally off the radar so anything in their pipeline is hidden from public view.

Regards.

Yeah Potnak, I understand where you're coming from but none of us know what RF's current holding is. For all we know their plan is to sell half to recoup some funds now but hold the other half for potentially much higher gains if a license deal comes along. If their business model is simply to sell their shares as soon as they get them then it doesn't provide much scope for making a profit if it tanks the sp in the process. Yes, they'll be handed more shares to make up any losses but I doubt their goal is simply to break even. RF's own share price is garbage so you'd think they'd be looking to invest (stop laughing at the back), in order to turn their own fortunes around.

Hi Laz - it would depend on who is buying the shares. Knowing P1a appears encouraging might suggest it's a buy and hold if an on-license is looking likely.

Another news article - https://www.businessweekly.co.uk/posts/sareum-says-so-long-to-sad-and-hi-to-happy-as-trials-hurdle-is-cleared

The company behind Krone's original post seem, uh, 'interesting' - https://en.wikipedia.org/wiki/BNN_Breaking

Yes, it's positive but it does have a whiff of AI generated text about it.

Evening Leggster - in a few weeks 1801 should be in a very different position compared to 6mths ago. I wonder if the BoD & the city would contemplate a raise at that point. Yes it would mean heavy dilution, say 16.6m shares at 30p to raise £5m but at least we'd know the company would be relatively insulated from lowball offers and RF could be told to foxtrot oscar. With good safety data from 1801 I don't see why the city wouldn't accept that option - it's not as if we'd be some new and unknown company with only an idea on a computer screen.

It could be worse FF, you could have a season ticket for the Shire.

(Sorry, I know nothing about football - as a child my punishment for being bad was dad would take me to Brockville. That put me on the straight and narrow pretty quickly.)

If any of the HNWs are still invested, I wonder at what point they step in. I presume these people are 'connected' and won't let the company rot away to the point of no return.

Regarding the value of the company, we have to remember that 1801 has value and that value will be based on similar compounds. Think of it this way, if you dig up a 20 carat diamond, is it worth the same as similar diamonds or just the value of your shovel?

Some light bedtime reading - https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf

This site is interesting, you can use filters on the charts to isolate P1 Immunology deals etc. - https://www.bio.org/ia-reports/emerging-therapeutic-company-investment-and-deal-trends

Regards.

Thanks PCS - interesting stuff - every day is a school day.

I think they've put out the RNS ahead of full 1a completion only to steady/reverse the sp decline.

The Melbourne clinic does lots of other trials at any one time so without knowing their throughput, it's hard to say how many people are left in the MAD phase. I'd guess just a few weeks to go.

As for the people here complaining about the 'subject to financing' bit of the RNS, it's just a standard thing like every TV advert saying terms and conditions apply.

Onwards!

Hi SOG - I'm with Damion on this, the RNS stated a private biopharma company whereas MEI are publicly traded. I'm still torn between Boundless Bio where the CSO is Chris Hassig whose name appears on most of the Sierra 737 patent applications and Sierra itself under GSK's protection.

One last post before I pack it in for the evening. I presume if we have top notch 1a results then rather than the sp increasing by say, 50%, we should increase by the notional value of the compound divided by the number of shares e.g. if a brilliant P1a drug in the psoriasis field is worth £100m, then that would add roughly £1.40 to the sp?